← Return to all swing-trade opportunities
TMO — Oversold Bullish Reversal
Status: Invalidated
Scanner score: 20.0/100
Why this was flagged
TMO was identified as a bullish technical setup based on the Oversold Bullish Reversal pattern. The scanner found a score of 20.0/100 using trend alignment, momentum, price action, volume, and risk-management rules. Monitor update: Latest daily-chart analysis no longer reports a bullish long setup.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
Thermo Fisher Scientific Inc (TMO) caught attention because its computer score was 20 out of 100. This is a low score, which means the stock looks weak right now. The scanner uses a method called "Oversold Bullish Reversal." This happens when a stock price drops a lot, possibly too much. Think of it like a ball falling fast; sometimes, after a big drop, it stops and bounces back up. The scanner looks for signs that the price might start to go up again after this steep slide.
What the price plan means
The plan says to watch prices between $603.18 and $607.03. If the stock stays within this range, it is valid. If the price falls below $580.06, the idea is wrong, and you stop watching it. This is called the "invalidation price." The plan aims for two goal prices. The first goal is $649.42. The second is $672.54. The reward-to-risk ratio is 2. This means that for every dollar you might lose, you hope to make two dollars if the stock goes up. It is a plan for potential profit, not a promise.
What could make the idea fail
The plan fails if the price goes below $580.06. Another risk is that the stock keeps falling instead of bouncing. The scanner saw a Relative Strength Index (RSI) of 34.79. An RSI below 30 is usually very low. Being near this level suggests the stock is tired, but it does not guarantee a bounce. Also, the trading volume is normal, not high, so there is not extra excitement buying the stock yet.
Important reminder
This information is for learning only. It is not financial advice. Stocks can go down and lose value. Always do your own research. A scanner score is just one number. It does not tell you the company’s health or future news. Never put in money you cannot afford to lose. Trading involves risk. This setup has an expiration date of September 21, 2026. After that, the data is old.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Positive (High confidence)
Thermo Fisher Scientific is experiencing a positive reception from analysts, with UBS upgrading its rating to Buy and raising the price target to $730, citing expectations of a return to mid-single-digit organic revenue growth and operating margin expansion by 2027. The company recently reported strong Q2 2026 earnings that exceeded Wall Street expectations and raised its full-year outlook. Industry reports indicate growing markets in diagnostics and research proteins, sectors where Thermo Fisher is a key player. Additionally, the company is integrating AI into its clinical supply chain operations to enhance logistics. Despite positive momentum, the InvestingPro Fair Value analysis suggests the stock may be overvalued, and broader macroeconomic risks remain a factor to consider.
Potentially supportive context
- UBS upgraded the stock rating from Neutral to Buy and increased the price target to $730, projecting 5% to 6% organic revenue growth by 2027.
- The company delivered strong Q2 2026 earnings that surpassed expectations and raised its full-year outlook.
- Market reports forecast growth in the IVD raw materials and recombinant protein sectors, areas where Thermo Fisher is a leading participant.
Risks and caution items
- InvestingPro’s Fair Value analysis suggests the current stock price might be overvalued.
- The company faces potential headwinds from broader macroeconomic challenges, including inflation and interest rate changes.
- The technical setup indicates the stock is currently in an 'Oversold' state, which is a short-term technical condition rather than a fundamental strength.
Latest reviewed article: Sep 10, 2026 11:37 am
Recent related articles
Bryn Talkington, Stephen Weiss, Joseph M. Terranova, and Kari Firestone shared their "Final Trades" on CNBC's "Halftime Report." Weiss picked Wells Fargo, citing strong Q2 results. Terranova chose Nutrien despite an earnings miss but strong sales, and Firestone recommended Thermo Fisher Scientific…
Christy Owings from Thermo Fisher Scientific discusses how AI is transforming clinical supply chain operations across the Americas. She emphasizes AI as a complement to human expertise, streamlining site logistics through automation and data synthesis for sensitive products. Owings also notes AI's…
UBS analysts predict that Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to achieve mid-single-digit organic revenue growth by 2027. The article mentions that a premium subscription is required to read the full report from MT Newswires.
UBS has upgraded Thermo Fisher Scientific (NYSE:TMO) to Buy from Neutral, increasing its price target to $730 from $540. The upgrade is based on expectations of a return to at least 5% to 6% organic revenue growth by 2027, operating margin expansion,…
UBS has upgraded Thermo Fisher Scientific (NYSE:TMO) from Neutral to Buy, increasing its price target to $730 from $540, citing an expected return to at least 5% to 6% organic revenue growth by 2027 and double-digit earnings per share growth. The firm…
This article highlights how Zacks' various investment strategies, including Zacks Rank, Recommendation Upgrades, Focus List, and specialized portfolios like ECAP and ECDP, have consistently outperformed major market indexes. It showcases specific examples like Oportun Financial, Uranium Royalty, Amgen, Palantir Technologies, and Thermo…
This article illustrates the significant growth an investment in Thermo Fisher Scientific (NYSE: TMO) would have achieved over 15 years. An initial investment of $1000 in TMO stock 15 years ago would now be worth $11,561.90, representing an annualized return of 17.57%.…
A new report forecasts the global research use recombinant protein market to grow from $1.11 billion in 2026 to $1.55 billion by 2031, driven by expanding therapeutic pipelines and increased preclinical research in advanced therapies. The market growth will be significantly influenced…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- RSI is near oversold territory with bullish candle confirmation.